Upadacitinib | CAS 1310726-60-3 - Request Quote
Upadacitinib
| SZ CAT No: | SZ-U005001 |
| CAS No | 1310726-60-3 |
| Mol.F. | C17H19F3N6O |
| Mol.Wt. | 380.4 |
| Inv. Status | In Stock |
| Rel. CAS No | 2050057-56-0 (hemihydrate) |
| Shipping Condition | Room Temperature |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Upadacitinib is chemically (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide. Upadacitinib is supplied with detailed characterization data compliant with regulatory guideline. Upadacitinib can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Upadacitinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 1310726-60-3
Purchase 1310726-60-3
Order 1310726-60-3
Enquire 1310726-60-3
price of 1310726-60-3
1310726-60-3 Supplier
1310726-60-3 Manufacturer
1310726-60-3 Exporter
buy high quality Upadacitinib
Purchase Upadacitinib
Upadacitinib suppliers
Upadacitinib manufacturers
Upadacitinib price
Order Upadacitinib
Enquire Upadacitinib
Upadacitinib cost
Upadacitinib Supplier
Upadacitinib Distributor
Upadacitinib for Method Validation
Upadacitinib Reference Standard
Upadacitinib for ANDA Filing
Upadacitinib for Forced Degradation Studies
Upadacitinib Identification Standards
Upadacitinib for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.